Calidi Biotherapeutics Names New CEO to Drive Oncology Research Forward

Calidi Biotherapeutics has selected Eric Poma, Ph.D., as its new Chief Executive Officer, signaling a strategic leadership transition to advance the company's pioneering cancer treatment technologies. Poma's appointment, effective April 22, comes as the biotech firm prepares to escalate its clinical development efforts in oncology research.

With over three decades of experience in the biotechnology sector, Poma brings significant leadership expertise to the role. His previous leadership at Molecular Templates includes successfully raising more than $250 million in funding and establishing strategic partnerships with prominent pharmaceutical companies such as Takeda, Vertex, and Bristol Myers Squibb.

The leadership change coincides with Calidi's preparations for a critical dose-escalation trial of CLD-201, a promising therapeutic approach targeting solid tumors. Poma's extensive background positions the company to potentially advance its innovative stem cell-based virotherapy platform, which aims to enhance immune system responses against cancer.

Calidi's proprietary technology focuses on developing off-the-shelf, universal cell-based delivery platforms designed to protect and amplify oncolytic viruses. The company's approach uniquely combines stem cell technologies with viral payloads, potentially offering more effective and safer treatment options for patients with challenging oncological conditions, including high-grade gliomas and metastatic solid tumors.

Outgoing CEO Allan Camaisa will continue to support the organization as a Board member, ensuring a smooth leadership transition. The strategic appointment of Poma underscores Calidi Biotherapeutics' commitment to pushing the boundaries of cancer treatment through cutting-edge scientific research and development.